Evidence map›Paper›PMID 37765098›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Metabolomic Profile, Plasmatic Levels of Losartan and EXP3174, Blood Pressure Control in Hypertensive Patients and Their Correlation with COVID-19.

Kamila A Queiroz, Everton P Vale, Manuel Martín-Pastor, Lílian G S Sólon, Francisco F O Sousa

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Kamila A QueirozGraduate Program on Pharmaceutical Sciences, Department of Biological & Health Sciences, Federal University of Amapa, Macapa 68903-419, Brazil.
Everton P ValeLaboratory of Quality Control, Bromatology and Microbiology, Department of Biological & Health Sciences, Federal University of Amapa, Macapa 68903-419, Brazil.ORCID 0000-0001-7793-9663
Manuel Martín-PastorUnidade de Resonancia Magnetica, Área de Infraestruturas de Investigación, Campus Vida, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0001-6024-1656
Lílian G S SólonGraduate Program on Pharmaceutical Sciences, Department of Biological & Health Sciences, Federal University of Amapa, Macapa 68903-419, Brazil.
Francisco F O SousaGraduate Program on Pharmaceutical Sciences, Department of Biological & Health Sciences, Federal University of Amapa, Macapa 68903-419, Brazil.ORCID 0000-0002-7366-1622
Universidade Federal do Amapá · BRUniversidade de Santiago de Compostela · ES

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001FAPEAP, SESA/AP, DECIT, CNPq-PPSUS Program 2018 35/2019FAPEAP, SESA/AP, DECIT, CNPq-PPSUS Program 2020 004/2021
6 · The paper itself

Abstract

Systemic arterial hypertension (SAH) is one of the most prevalent chronic diseases worldwide and is related to serious health complications. It has been pointed out as a major risk factor for COVID-19. This study aimed to determine the impact of COVID-19 on the metabolomic profile, the correlation with the plasmatic levels of losartan and its active metabolite (EXP3174), biochemical markers, and blood pressure (BP) control in hypertensive patients.

Indexed as

COVID-19EXP3174hypertensionlosartanmetabolomicsplasmatic level

Identifiers

PMID37765098
PMCPMC10535928
OpenAlexW4386713204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.